基于HBV DNA与ALT治疗阈值下调可能难以达到降低HBV相关终末期肝病发生的目的

肝脏 ›› 2023, Vol. 28 ›› Issue (2): 155-156.

基于HBV DNA与ALT治疗阈值下调可能难以达到降低HBV相关终末期肝病发生的目的

肖丽, 王欣茹, 咸建春

225300 江苏泰州市人民医院感染暨肝病科

收稿日期:2023-01-31 出版日期:2023-02-28 发布日期:2023-04-10
通讯作者: 咸建春,Email: xianjc09@163.com
基金资助:
泰州市科技支撑计划(社会发展)项目(TS201813);泰州市人民医院院级课题(QDJJ202108)

Received:2023-01-31 Online:2023-02-28 Published:2023-04-10

摘要/Abstract

摘要： 为进一步降低HBV相关终末期肝病的发生,中华医学会肝病学分会制订了《扩大慢性乙型肝炎抗病毒治疗的专家意见》,其中推荐意见 2 、3的实际结果是下调CHB抗病毒治疗的HBV DNA与ALT阈值。但经认真研读本文背景资料引用的两篇主要文献,发现HBV DNA与ALT不是当前抗病毒适应证之外HCC等终末期肝病发生的风险因素或风险权重较低,故基于HBV DNA与ALT治疗阈值下调可能难以达到降低HBV相关终末期肝病发生的目的,而应进一步基于年龄、性别、白蛋白、血小板等综合评估。

肖丽, 王欣茹, 咸建春. 基于HBV DNA与ALT治疗阈值下调可能难以达到降低HBV相关终末期肝病发生的目的[J]. 肝脏, 2023, 28(2): 155-156.

参考文献

[1] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 中华肝脏病杂志,2019,27(12):938-961.
[2] 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见. 中华肝脏病杂志,2022,30(2):131-136.
[3] Tong MJ, Hsien C, Hsu L, et al. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology, 2008, 48(4):1070-1078.
[4] Sinn DH, Kim SE, Kim BK, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepat, 2019, 26(12):1465-1472.
[5] de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol, 2003, 39 Suppl 1:S3-25.
[6] Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol, 2006,4(8):936-962.
[7] ACT-HBV Asia-Pacifific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int, 2006, 26:47-58.
[8] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2007, 45:507- 539.
[9] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10(1):1-98.
[10] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2):370-398.
[11] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4):1560-1599.
[12] 鲁凤民,封波,郑素军,等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状. 临床肝胆病杂志, 2021, 37(6):1268-1274.
[13] Sun Y, Wu X, Zhou J, et al. Persistent low level of hepatitis B virus promotes ?brosis progression during therapy. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591.
[14] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol, 2021, 9(6):850-859.
[15] Jang JW, Choi JY, Kim YS, et al. Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol, 2018, 16(12): 1954-1963.
[16] Iloeje UH, Yang HI, Chen CJ, et al. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int, 2012, 32(9): 1333-1341.
[17] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA,2006, 295(1):65-73.